NCT01295645View on ClinicalTrials.gov

Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 17, 2011

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2026

Conditions
Transplantation Infection
Interventions
DRUG

Cidofovir

0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.

OTHER

No Cidofovir

Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER